Dogwood Therapeutics (DWTX) AI Stock Analysis

• Market Cap: $12.06M
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.76
• Revenue Growth: N/A
• EPS Growth: -295.27%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -8.20
• Shares Outstanding: 2,293,162
• 10 Day Avg. Volume: 77,367
• 30 Day Avg. Volume: 1,536,657
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.29
• Enterprise Value/Market Cap: 8.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -5.60K
• Enterprise Value/Ebitda: -5.31
• 1Y Price Target: $21.00
• Price Target Upside: 299.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ―

Dogwood Therapeutics' overall stock score reflects its financial challenges typical of early-stage biotech firms, with no revenue and significant reliance on external financing. However, the recent debt conversion strengthens the balance sheet and boosts investor confidence. Technical indicators suggest neutral momentum, with a speculative valuation.

Positive Factors

Debt Conversion

The conversion of $19.5 million in debt into equity reduces financial burdens, allowing the company to focus on clinical trials and potentially enhancing investor confidence.

Strategic Partnerships

Strategic partnerships provide upfront payments, milestone payments, and royalties, which are crucial for funding R&D and advancing drug candidates without immediate revenue.

Focus on Unmet Medical Needs

By targeting oncology and rare diseases, Dogwood Therapeutics positions itself in high-demand areas with significant unmet needs, potentially leading to successful drug development and market penetration.

Negative Factors

No Revenue Generation

The absence of revenue generation poses a significant risk, as the company remains reliant on external financing and partnerships to sustain operations, which may not be sustainable long-term.

Negative Cash Flow

Negative cash flow indicates high cash burn typical in biotech, necessitating continuous external funding, which could become challenging if market conditions change or partnerships falter.

Significant Net Losses

Persistent net losses reflect high operational costs without offsetting income, highlighting the financial strain and risk of continued operations without successful product commercialization.

Dogwood Therapeutics Business Overview & Revenue Model

Company Description

Dogwood Therapeutics (DWTX) is a biopharmaceutical company focused on the discovery and development of innovative therapies to address unmet medical needs. Specializing in the areas of oncology and rare diseases, Dogwood Therapeutics leverages advanced biological insights and cutting-edge technology to create targeted treatments that improve patient outcomes. The company is committed to advancing personalized medicine through a robust pipeline of clinical candidates designed to tackle some of the most challenging conditions in healthcare.

How the Company Makes Money

Dogwood Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company engages in strategic partnerships with larger pharmaceutical firms to co-develop and market its therapies, often receiving upfront payments, milestone payments, and royalties on sales. Additionally, Dogwood Therapeutics may secure funding through research grants and collaborations with academic institutions, contributing to its R&D efforts. Licensing agreements for its proprietary technologies and intellectual property serve as another significant revenue stream, allowing the company to monetize its innovations while expanding its market reach.

Dogwood Therapeutics Financial Statement Overview

Summary

Dogwood Therapeutics exhibits typical characteristics of early-stage biotech firms with no revenue and significant losses. While it has a strong equity base and low leverage, the company's financial health is heavily reliant on external financing, posing a risk if revenue generation does not commence soon.

Income Statement

Dogwood Therapeutics has consistently reported no revenue over the years, which is typical for early-stage biotechnology firms. The company has significant net losses, indicating high R&D and operational costs with no offsetting income. The lack of revenue and consistent losses are concerning, but expected in this sector.

Balance Sheet

The company's balance sheet shows a strong equity base and low leverage, with a Debt-to-Equity Ratio of 0, indicating no debt burden. However, equity is primarily financed by cash injections, reflecting a reliance on external funding. This suggests a stable but potentially unsustainable financial structure without revenue generation.

Cash Flow

Dogwood Therapeutics has negative free cash flow, which reflects its cash burn typical in biotech. The Operating Cash Flow to Net Income Ratio indicates efficient cash management relative to reported losses. However, continued reliance on financing activities to sustain operations could pose long-term risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-17.26K	0.00	0.00	0.00	0.00	0.00
EBITDA	-18.19M	-12.25M	-5.45M	-12.32M	-15.64M	-10.01M
Net Income	-24.74M	-12.35M	-5.30M	-12.25M	-15.96M	-10.35M
Balance Sheet
Total Assets	96.69M	94.31M	4.17M	8.37M	15.78M	31.47M
Cash, Cash Equivalents and Short-Term Investments	13.40M	14.85M	3.32M	7.03M	14.01M	29.80M
Total Debt	186.99K	15.59M	0.00	0.00	0.00	0.00
Total Liabilities	14.15M	30.03M	358.55K	1.04M	1.28M	1.53M
Stockholders Equity	82.54M	64.28M	3.81M	7.33M	14.50M	29.94M
Cash Flow
Free Cash Flow	-15.75M	-8.79M	-4.87M	-11.47M	-15.69M	-3.90M
Operating Cash Flow	-15.75M	-8.79M	-4.87M	-11.47M	-15.69M	-3.90M
Investing Cash Flow	3.76M	3.76M	0.00	0.00	0.00	0.00
Financing Cash Flow	22.50M	16.70M	1.16M	4.49M	-97.60K	33.38M

Dogwood Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.26
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DWTX, the sentiment is Negative. The current price of 5.26 is below the 20-day moving average (MA) of 5.92, below the 50-day MA of 5.68, and below the 200-day MA of 5.74, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 41.77 is Neutral, neither overbought nor oversold. The STOCH value of 7.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DWTX.

Dogwood Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DWTX	49 Neutral	$12.06M	-0.21	-97.54%	―	―	-295.27%
BRTX	48 Neutral	$11.86M	―	-137.09%	―	247.62%	-7.66%
BOLT	45 Neutral	$9.67M	-0.19	-81.33%	―	-62.68%	23.94%
MRKR	44 Neutral	$11.19M	―	-144.68%	―	44.55%	-17.92%
SNSE	40 Underperform	$10.95M	-0.41	-67.47%	―	―	9.63%
ACXP	39 Underperform	$10.03M	-0.45	-285.93%	―	―	53.79%

Dogwood Therapeutics Corporate Events

Dogwood Therapeutics Strengthens Balance Sheet with Debt Conversion

On March 12, 2025, Dogwood Therapeutics entered into a Debt Exchange and Cancellation Agreement with Conjoint Inc., converting $19.5 million in debt into equity by issuing Series A-1 Non-Voting Convertible Preferred Stock. This strategic move, supported by the company’s largest shareholder CK Life Sciences Int’l., strengthens Dogwood’s balance sheet and underscores confidence in its lead product, Halneuron®, which is being developed as a non-opioid pain treatment. The agreement allows Dogwood to focus on its Phase 2b clinical trial for chemotherapy-induced neuropathic pain without the burden of debt, potentially enhancing its attractiveness to investors.